Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04827420 · ClinicalTrials.gov registry record · NA

Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)

A NA study of Tobacco Use Cessation, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
NA
Development phase
3,000
Enrollment target
1
Study location

NCT04827420 is a NA study of Tobacco Use Cessation that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 3,000 participants, above the 801-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (275% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04827420, a NA study of Tobacco Use Cessation, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
NA
Development phase
3,000 participants
Enrollment target
1
Study location

Study Summary

The over-arching research question is: Does message (Advise) and referral approach (Refer) influence a patient's willingness to "opt-in" to receive a call from an Illinois Tobacco Quitline (ITQL) smoking cessation coach in patients at MSHC. Primary UH3 study aim: Compare the effect of the portal-delivered Choice message (Arm 1) to the Information-only message (Arm 3) on linkage to the Illinois Tobacco Quitline (i.e., spoke to a Quitline coach). Secondary UH3 aims are to: Examine the reach of the patient portal for delivering "Advise" and "Refer" at 4 weeks. Reach is defined as a patient opening the portal-delivered provider message across all three Arms. Compare the effect of the Quit message (Quit, Arm 2) to Information-only (Arm 3) on linkage to ITQL. Compare the effect of the Facilitated-referral messages (opt-in link in the message: Arm 1 \& 2) vs. Self-referral (Information-only, Arm 3) on linkage to the ITQL (speaking to an ITQL coach) at four weeks. Compare the effect of the portal-message content of the Choice message (Arm 1) vs. the Quit message (Arm 2) on linkage acceptance (opting in to be called by the ITQL) at 4 weeks. Compare the effectiveness of re-engagement message 1 to message 2 for linkage to the ITQL among patients who opted-in to an ITQL call but who were not reached after 3 attempts. Evaluate the cost-effectiveness of using a patient portal to advise patients to change their smoking behavior and refer them to the ITQL. We will compare the costs associated with our project to the costs associated with advising and referring patients during clinical appointments.

Conditions Studied

Tobacco Use Cessation

Interventions

  • BEHAVIORAL Mi Quit Care

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2025-01-28
Est. Completion 2027-08-01
Phase NA

Sponsor

University of Illinois at Chicago

430 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04827420

The ClinicalTrials.gov registry entry for NCT04827420 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 801-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (275% higher). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 1 intervention - of which Mi Quit Care is the first listed.

NCT04827420 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04827420 about?

NCT04827420 is a clinical study titled "Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)". The over-arching research question is: Does message (Advise) and referral approach (Refer) influence a patient's willingness to "opt-in" to receive a call from an Illinois Tobacco Quitline (ITQL) smoking cessation coach in patients at MSHC. Primary UH3 study aim: Compare the effect of the portal-de...

What is the current status of trial NCT04827420?

This trial is currently recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2025-01-28. Estimated completion is 2027-08-01.

What conditions does trial NCT04827420 study?

This clinical trial studies the following conditions: Tobacco Use Cessation.

What interventions are being tested in trial NCT04827420?

The interventions under investigation include: Mi Quit Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT04827420?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04827420 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tobacco Use Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tobacco Use Cessation

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.